Locust Walk Acquisition filed an S-4 outlining terms of its merger deal with eFFECTOR Therapeutics.
Pending regulatory and shareholder approvals, upon completion of the merger eFFECTOR Therapeutics is expected to list on the Nasdaq under EFTR. The deal is expected to close in the third quarter.
As of June 7 there was approximately $175 million in the SPAC’s trust account, according to the filing. The merger is further supported by a $60 million PIPE.
A shareholder vote date on the acquisition has not been filed.
eFFector develops therapeutic drugs for the treatment of cancer. Read more.
